TRex Bio
TRXB on NasdaqBiological products (no diagnostic substances)
Dilution Known so far: 8.3M possible new shares · no effective shelf · not yet read: warrants, converts, options, ATM. Every source
TRex Bio’s latest filing is a Schedule 13G from . Every TRex Bio filing is below, newest first.
Insiders 2 insiders bought $3.8M of TRex Bio stock on the open market in the last 90 days. Every trade
Passive stake of 5% or more
IPO registration
Priced and listed · S-1/A filed Oct 5, 2026
- Final prospectus, offering priced 424B4
- Registration declared effective EFFECT
- Shares registered for exchange listing 8-A12B
- Amended registration S-1/AFirst filing
All filings
Each other tab counts its kind among the 38 most recent EDGAR filings.
Results, 8-Ks and Major or Notable filings come first, then registrations and share actions, then everything else, newest first. Routine filings are kept here unmarked; insider filings are summed up in one line.
No TRXB filings found yet.
Offerings and dilution 5
| Date | Form | What it is |
|---|---|---|
| Oct 9, 2026 | S-8 | Employee stock plan registration |
| Oct 9, 2026 | 424B4 | Prospectus |
| Oct 8, 2026 | EFFECT | Registration declared effective |
| Oct 5, 2026 | S-1/A | Registration for a share sale (amended) Key exhibits: Underwriting or sales agreement (EX-1.1), Warrants or notes (EX-4.1), Warrants or notes (EX-4.2), Material contract (EX-10.4), Material contract (EX-10.5), Material contract (EX-10.6), Material contract (EX-10.10), Material contract (EX-10.11), Material contract (EX-10.12), Material contract (EX-10.13), Material contract (EX-10.14), Material contract (EX-10.15) |
| Sep 18, 2026 | S-1 | Registration for a share sale Key exhibits: Material contract (EX-10.1), Material contract (EX-10.2), Material contract (EX-10.3), Material contract (EX-10.7), Material contract (EX-10.8), Material contract (EX-10.9) |
Insiders 23
| Date | Form | What it is |
|---|---|---|
| Oct 15, 2026 | Form 4 | Alexandria Venture Investments, LLC (10% owner) bought 178,571 TRXB at $14.00, worth $2.5M |
| Oct 13, 2026 | Form 4 | SVLSF VI, LLC (10% owner) bought 92,857 TRXB at $14.00, worth $1.3M |
| Oct 13, 2026 | Form 4 | Joel S Marcus (Director) converted 41,871 TRXB |
| Oct 8, 2026 | Form 3 | New insider |
| Oct 8, 2026 | Form 3 | New insider |
| Oct 8, 2026 | Form 4 | Joel S Marcus (Director) reported option or other derivative trades in TRXB |
| Oct 8, 2026 | Form 4 | Travis Alan Coy (Director) reported option or other derivative trades in TRXB |
| Oct 8, 2026 | Form 4 | Michael Jay Ross (Director) reported option or other derivative trades in TRXB |
15 older insiders filings on EDGAR.
Ownership 4
| Date | Form | What it is |
|---|---|---|
| Oct 16, 2026 | Schedule 13D | Active stake of 5% or more |
| Oct 16, 2026 | Schedule 13G | Passive stake of 5% or more |
| Oct 16, 2026 | Schedule 13D | Active stake of 5% or more |
| Oct 15, 2026 | Schedule 13G | Passive stake of 5% or more |
Governance 1
| Date | Form | What it is |
|---|---|---|
| Oct 13, 2026 | 8-K | Amends its charter or bylaws |
Other 5
Possible new shares
Known so far: 8.3M possible new shares · no effective shelf · not yet read: warrants, converts, options, ATM.
- 8.3M new shares from the 424B4 of Oct 9, 2026
Not read yet: warrants, convertible notes, options and RSUs and an ATM program.
Listing compliance
No listing notices in the 8-K item 3.01 filings SEC Tracker has read.
Dates and rules are as stated in each 8-K item 3.01 filing; a blank means the filing did not state one. Read the filing for the full terms. All open notices
Trading halts
No trading halts for TRXB since Feb 22, 2019, when SEC Tracker began reading the Nasdaq Trader feed.
Halt times and codes from the Nasdaq Trader trade halts feed, which lists Nasdaq and other exchange halts. Filings matched by SEC Tracker from EDGAR by company and time. Not investment advice. All recent halts
Coming up
- Offering lock-up ends, about 180 days after the 424B4 of Oct 9 424B4, filed Oct 9
- Primary completion of the trial "Phase 1a/1b Study of TRB-061 in Healthy Participants & Patients With Atopic Dermatitis" ClinicalTrials.gov NCT06934252
Dates and exhibits are as stated in each filing on EDGAR; a date no filing states is not shown. Not investment advice.
TRex Bio shares and listing
From the company's own filings; each row names its source. Not investment advice.
- Listing compliance8-K item 3.01No noticesin the filings read
Insider activity
2 insiders bought $3.8M of TRex Bio stock on the open market in the last 90 days.
- 10% owner bought $2.5M
- 10% owner bought $1.3M
Similar companies
Same SIC code (2836 Biological products (no diagnostic substances)) and public float not reported.
- Adaptimmune Therapeutics ADAP
- Adverum Biotechnologies ADVM
- AgomAb Therapeutics AGMB
- Alvotech ALVO
- Argenx ARGX